×
About 13,613 results

ALLMedicine™ Idiopathic Pulmonary Fibrosis Center

Research & Reviews  6,655 results

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idi...
https://doi.org/10.1038/s41467-020-18397-6
Nature Communications; John AE, Graves RH et. al.

Sep 17th, 2020 - The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). We identified a selective small molecule αvβ6 RGD-mimet...

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with ble...
https://doi.org/10.1080/03639045.2020.1825473
Drug Development and Industrial Pharmacy; Togami K, Maruta Y et. al.

Sep 17th, 2020 - Objective: Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic lung disease characterized by abnormal remodeling of the lung parenchyma with subsequent scarring of the alveolar structure. In this study, we examined the distribution ch...

Prognostic significance of forced vital capacity decline prior to and following antifib...
https://doi.org/10.1177/1753466620953783
Therapeutic Advances in Respiratory Disease; Aono Y, Nakamura Y et. al.

Sep 15th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initi...

Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathw...
https://doi.org/10.1165/rcmb.2020-0227OC
American Journal of Respiratory Cell and Molecular Biology; Berhan A, Harris T et. al.

Sep 14th, 2020 - Pathological changes in the biomechanical environment are implicated in the progression of idiopathic pulmonary fibrosis (IPF). Stiffened matrix augments fibroblast proliferation, differentiation and activates transforming growth factor beta-1 (TG...

see more →

Guidelines  15 results

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice G...
https://www.atsjournals.org/doi/10.1164/rccm.201807-1255ST
Raghu, G.

Aug 31st, 2018 - This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and.

Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fib...
http://www.thoracic.org/statements/resources/interstitial-lung-disease/animal-models-pulm-fibrosis.pdf
R. Gisli Jenkins

Apr 30th, 2017 - Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clini.

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.
https://doi.org/10.1159/000464332
Respiration; International Review of Thoracic Diseases; Funke-Chambour M, Azzola A et. al.

Mar 27th, 2017 - Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the c...

The Intersection of GERD, Aspiration, and Lung Transplantation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948126
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A; Patti MG, Vela MF et. al.

May 24th, 2016 - Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophagea...

Treatment of Idiopathic Pulmonary Fibrosis.
https://doi.org/10.1513/AnnalsATS.201510-713CME
Annals of the American Thoracic Society; Carlos WG, Strek ME et. al.

Jan 5th, 2016 - Treatment of Idiopathic Pulmonary Fibrosis.|2016|Carlos WG,Strek ME,Wang TS,Patel H,Raghu G,|drug therapy,

see more →

Drugs  4 results see all →

Clinicaltrials.gov  6,755 results

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idi...
https://doi.org/10.1038/s41467-020-18397-6
Nature Communications; John AE, Graves RH et. al.

Sep 17th, 2020 - The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). We identified a selective small molecule αvβ6 RGD-mimet...

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with ble...
https://doi.org/10.1080/03639045.2020.1825473
Drug Development and Industrial Pharmacy; Togami K, Maruta Y et. al.

Sep 17th, 2020 - Objective: Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic lung disease characterized by abnormal remodeling of the lung parenchyma with subsequent scarring of the alveolar structure. In this study, we examined the distribution ch...

Prognostic significance of forced vital capacity decline prior to and following antifib...
https://doi.org/10.1177/1753466620953783
Therapeutic Advances in Respiratory Disease; Aono Y, Nakamura Y et. al.

Sep 15th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initi...

Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathw...
https://doi.org/10.1165/rcmb.2020-0227OC
American Journal of Respiratory Cell and Molecular Biology; Berhan A, Harris T et. al.

Sep 14th, 2020 - Pathological changes in the biomechanical environment are implicated in the progression of idiopathic pulmonary fibrosis (IPF). Stiffened matrix augments fibroblast proliferation, differentiation and activates transforming growth factor beta-1 (TG...

see more →

News  179 results

FDA broadens nintedanib interstitial lung disease indication
https://www.mdedge.com/internalmedicine/article/218826/pulmonology/fda-broadens-nintedanib-interstitial-lung-disease?channel=39313
Mitchel L. Zoler

Mar 11th, 2020 - A new indication for the tyrosine kinase inhibitor nintedanib approved by the Food and Drug Administration on March 9, 2020, broadened the drug’s targeted population to include patients with chronic fibrosing interstitial lung diseases with a prog.

Roche pushes to kick-start lung therapy Esbriet after big writedown
https://www.reuters.com/article/us-roche-esbriet/roche-pushes-to-kick-start-lung-therapy-esbriet-after-big-writedown-idUSKBN20Q21O

Mar 3rd, 2020 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable int...

Idiopathic pulmonary fibrosis in an era of personalized medicine
https://www.mdedge.com/pulmonary-health-hub/article/217385/pulmonology/idiopathic-pulmonary-fibrosis-era-personalized?channel=284
Lisa Hack

Feb 18th, 2020 - Useful not only as a clinical overview but also for patient information, these up-to-date statistics elucidate the symptoms and prevalence of pulmonary fibrosis; and recommendations for personalized treatment. To see the data in action, start read.

Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
https://www.reuters.com/article/us-promedior-m-a-roche-hldg/roche-buys-u-s-drugmaker-promedior-for-up-to-1-4-billion-to-get-lung-drug-idUSKBN1XP1F0

Nov 15th, 2019 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Pr...

TKI preserved lung function in patients with fibrosing interstitial disease
https://www.mdedge.com/pulmonary-health-hub/article/209092/pulmonology/tki-preserved-lung-function-patients-fibrosing?channel=94
Ted Bosworth

Sep 30th, 2019 - MADRID – In patients with fibrosing lung diseases other than idiopathic pulmonary fibrosis (IPF), nintedanib, a tyrosine kinase inhibitor, substantially reduced the rate of decline in lung function, according to findings from a phase 3, placebo-co.

see more →

Patient Education  5 results see all →